Skip to main content
Year archive

Chong Kun Dang Pharmaceutical Corp. — 2023 filings

All 50 regulatory filings released by Chong Kun Dang Pharmaceutical Corp. (185750) in 2023, sourced directly from the official regulator.

50 Filings
2023 Period
2023 filings (50)
Filing Released Lang
주식등의대량보유상황보고서(일반)
Major Shareholding Notification
2023-12-21 Korean
주요사항보고서(무상증자결정)
Share Issue/Capital Change
2023-12-14 Korean
[기재정정]반기보고서 (2023.06)
Interim / Quarterly Report H1 2023
2023-11-14 Korean
분기보고서 (2023.09)
Interim / Quarterly Report 9M 2023
2023-11-14 Korean
투자판단관련주요경영사항(기술이전 계약 체결(HDAC6 저해제인 CKD-510의 연구, 임상개발 및 상업화 권리에 대한 기술수출 계약))
Regulatory Filings
2023-11-06 Korean
영업(잠정)실적(공정공시)
Earnings Release Q3 2023
2023-10-27 Korean
신탁계약해지결과보고서
Transaction in Own Shares
2023-10-19 Korean
주요사항보고서(자기주식취득신탁계약해지결정)
Transaction in Own Shares
2023-10-16 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification
2023-09-21 Korean
반기보고서 (2023.06)
Interim / Quarterly Report H1 2023
2023-08-11 Korean
영업(잠정)실적(공정공시)
Earnings Release Q2 2023
2023-07-28 Korean
공정거래자율준수프로그램운영현황(안내공시)
Governance Information
2023-07-21 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification
2023-06-22 Korean
투자판단관련주요경영사항(듀비에에스정(CKD-396) 식품의약품 안전처 국내 품목허가 승인)
Regulatory Filings
2023-06-09 Korean
기업지배구조보고서공시
Governance Information
2023-05-31 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Q1 2023
2023-05-15 Korean
투자판단관련주요경영사항(MSD 자누비아 품목의 국내 제반권리(판권, 제조권 등)에 대한 라이선스 도입의 건)
M&A Activity
2023-05-09 Korean
투자판단관련주요경영사항(듀비메트에스서방정(CKD-393) 식품의약품 안전처 국내 품목허가 승인)
Regulatory Filings
2023-05-02 Korean
영업(잠정)실적(공정공시)
Earnings Release Q1 2023
2023-04-28 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification
2023-03-29 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing
2023-03-29 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification
2023-03-23 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification
2023-03-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification
2023-03-23 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements
2023-03-22 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification
2023-03-17 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification
2023-03-17 Korean
[기재정정]사업보고서 (2022.12)
Annual Report FY 2022
2023-03-16 Korean
감사보고서제출
Audit Report / Information FY 2022
2023-03-14 Korean
사업보고서 (2022.12)
Annual Report FY 2022
2023-03-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing
2023-03-13 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification
2023-03-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification
2023-03-06 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification
2023-03-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing
2023-03-06 Korean
주주총회소집공고
AGM Information
2023-02-21 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement
2023-02-21 Korean
[기재정정]주주총회소집공고
AGM Information
2023-02-21 Korean
[기재정정]투자판단관련주요경영사항(항체-약물 접합체(Antibody-Drug Conjugate, ADC) 플랫폼 기술 도입 계약 체결)
M&A Activity
2023-02-17 Korean
주주총회소집결의
AGM Information
2023-02-16 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount
2023-02-16 Korean
신탁계약해지결과보고서
Transaction in Own Shares
2023-02-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing
2023-02-10 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing
2023-02-10 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification
2023-02-10 Korean
주요사항보고서(자기주식취득신탁계약해지결정)
Transaction in Own Shares
2023-02-09 Korean
투자판단관련주요경영사항(항체-약물 접합체(Antibody-Drug Conjugate, ADC) 플랫폼 기술 도입 계약 체결)
Regulatory Filings
2023-02-03 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release FY 2022
2023-02-03 Korean
공정거래자율준수프로그램운영현황(안내공시)
Governance Information
2023-01-27 Korean
신탁계약에의한취득상황보고서
Transaction in Own Shares
2023-01-18 Korean